190 related articles for article (PubMed ID: 17893613)
1. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.
Gomez-Camarero J; Salcedo M; Rincon D; Lo Iacono O; Ripoll C; Hernando A; Sanz C; Clemente G; Bañares R
Transplantation; 2007 Sep; 84(6):786-91. PubMed ID: 17893613
[TBL] [Abstract][Full Text] [Related]
2. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
5. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
9. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
[TBL] [Abstract][Full Text] [Related]
11. Late acute cardiac allograft rejection: new therapeutic options?
Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
[TBL] [Abstract][Full Text] [Related]
12. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function.
De Simone P; Carrai P; Precisi A; Petruccelli S; Baldoni L; Balzano E; Ducci J; Caneschi F; Coletti L; Campani D; Filipponi F
Transpl Int; 2009 Mar; 22(3):279-86. PubMed ID: 19054383
[TBL] [Abstract][Full Text] [Related]
13. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
[TBL] [Abstract][Full Text] [Related]
14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
15. Long-term experience with everolimus in kidney transplantation in the United States.
Cibrik D; Arcona S; Vasquez E; Baillie GM; Irish W
Transplant Proc; 2011 Sep; 43(7):2562-7. PubMed ID: 21911123
[TBL] [Abstract][Full Text] [Related]
16. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
Montagnino G; Sandrini S; Iorio B; Schena FP; Carmellini M; Rigotti P; Cossu M; Altieri P; Salvadori M; Stefoni S; Corbetta G; Ponticelli C
Nephrol Dial Transplant; 2008 Feb; 23(2):707-14. PubMed ID: 17890244
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of everolimus in lung transplant patients.
Parada MT; Alba A; Sepúlveda C; Melo J
Transplant Proc; 2011; 43(6):2313-5. PubMed ID: 21839261
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
